NCT04003168View on ClinicalTrials.gov

Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma

PHASE1UnknownINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

July 31, 2022

Study Completion Date

July 31, 2024

Conditions
Multiple Myeloma
Interventions
DRUG

Human BCMA targeted T Cells Injection

Autologous genetically modified anti-BCMA CAR transduced T cells

Trial Locations (3)

200003

RECRUITING

Shanghai Changzheng Hospital, Shanghai

325000

RECRUITING

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

Unknown

RECRUITING

The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou

Sponsors
All Listed Sponsors
collaborator

Shanghai Changzheng Hospital

OTHER

collaborator

First Affiliated Hospital of Wenzhou Medical University

OTHER

collaborator

The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine

OTHER

lead

Hrain Biotechnology Co., Ltd.

INDUSTRY